Endo International PLC (ENDP): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Endo International ( ENDP) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.8%. By the end of trading, Endo International rose $0.72 (1.1%) to $66.86 on average volume. Throughout the day, 2,864,743 shares of Endo International exchanged hands as compared to its average daily volume of 2,475,400 shares. The stock ranged in a price between $64.82-$68.79 after having opened the day at $64.82 as compared to the previous trading day's close of $66.14. Other companies within the Drugs industry that increased today were: Idera Pharmaceuticals ( IDRA), up 17.8%, Trevena ( TRVN), up 11.4%, Actinium Pharmaceuticals ( ATNM), up 9.0% and CytRx Corporation ( CYTR), up 7.9%.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $7.7 billion and is part of the health care sector. Shares are down 2.0% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and weak operating cash flow.

On the negative front, Conatus Pharmaceuticals ( CNAT), down 15.6%, Tekmira Pharmaceuticals Corporation ( TKMR), down 14.5%, Exelixis ( EXEL), down 12.4% and Clovis Oncology ( CLVS), down 12.4% , were all laggards within the drugs industry with Biogen Idec ( BIIB) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds